# Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers

> **NCT01143727** · PHASE4 · COMPLETED · sponsor: **Healthpoint** · enrollment: 20 (actual)

## Conditions studied

- Diabetic Foot Ulcers

## Interventions

- **DRUG:** Santyl
- **DRUG:** Tegaderm Hydrogel

## Key facts

- **NCT ID:** NCT01143727
- **Lead sponsor:** Healthpoint
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-10
- **Final completion:** 2012-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01143727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01143727, "Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT01143727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*